Risk-Adapted Treatment in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: The SWENOTECA Management Program

To offer minimized risk-adapted adjuvant treatment on a nationwide basis for patients with clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT). The aim was to reduce the risk of relapse and thereby reducing the need of later salvage chemotherapy while maintaining a high cure r...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical oncology 2009-05, Vol.27 (13), p.2122-2128
Hauptverfasser: Tandstad, Torgrim, Dahl, Olav, Cohn-Cedermark, Gabriella, Cavallin-Stahl, Eva, Stierner, Ulrika, Solberg, Arne, Langberg, Carl, Bremnes, Roy M, Laurell, Anna, Wijkstrøm, Hans, Klepp, Olbjørn
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!